Caroline Schmidt
Ophthalmology · Houston, TXNPI 1760773790
Payments from drug & device makers
Across 52 payments — averaging $101.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$3K
- AbbVie$1K
- Carl Zeiss Meditec, Inc.$825
- Tarsus Pharmaceuticals, Inc.$194
- Bausch & Lomb, A Division Of Bausch Health US, LLC$92
- Alcon$75
- plus $363 from 11 others
What the payments were for
- Consulting fees$2,52548%
- Speaking & faculty fees$1,50028%
- Food & beverage$1,27724%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 5 | $2,671 |
| AbbVie(2 entities) | 18 | $1,082 |
| Carl Zeiss Meditec, Inc. | 1 | $825 |
| Tarsus Pharmaceuticals, Inc. | 4 | $194 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $92 |
| Alcon | 3 | $75 |
| Bausch & Lomb Americas Inc. | 4 | $72 |
| Novartis | 3 | $52 |
| Iridex Corporation | 1 | $51 |
| Aerie Pharmaceuticals, Inc. | 2 | $44 |
| Glaukos Corporation | 1 | $32 |
| Genentech USA, Inc. | 1 | $26 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Akorn, Inc. | 1 | $20 |
| Thea Pharma Inc. | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $17 |
| Quidel Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$2,500
- Kahook Dual Blade$2,500
- VERACITY SURGICAL$825
- DURYSTA$700
- RESTASIS$124
- XDEMVY$123
How this compares
$5,302 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 161 | $106,757 |
| ProlensaBromfenac Sodium | 62 | $23,786 |
| CombiganBrimonidine Tartrate/Timolol | 45 | $23,259 |
| Latanoprost | 1,386 | $21,350 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 907 | $19,037 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 71 | $16,088 |
| Prednisolone Acetate | 482 | $15,394 |
| Brimonidine Tartrate | 505 | $14,460 |
| Travoprost | 47 | $13,425 |
| Brinzolamide | 63 | $13,412 |
| RhopressaNetarsudil Mesylate | 25 | $11,806 |
| VyzultaLatanoprostene Bunod | 16 | $9,199 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 45 | $8,879 |
| Alphagan PBrimonidine Tartrate | 16 | $7,873 |
| Bromfenac Sodium | 48 | $6,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $1,082 | $137,889222 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $92 | $23,78662 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $44 | $11,80625 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $72 | $9,19916 claims |
| AlconSimbrinza | $75 | $6,61425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Houston
- David BrownHouston$51.7M
- John MichelettiHouston$3.3M
- Michael CaplanHouston$1.4M
- Shaheen KavoussiHouston$1.3M
- Kevin JongHouston$1.2M
- Stephen SladeHouston$1.2M
- Rosa TangHouston$1.1M
- Zaina Al-MohtasebHouston$1.1M
- Fiaz ZamanHouston$1M
- Stephen PflugfelderHouston$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.